Page last updated: 2024-08-18

thiophenes and Hematologic Malignancies

thiophenes has been researched along with Hematologic Malignancies in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brigandi, RA; Chen, C; Gauvin, J; Harrison, SJ; Kumar, R; Morris, SR; Opalinska, JB; Smith, DA; Spencer, A; Yoon, SS	1
Allen, CE; Arceci, RJ; Cornfeld, M; Dunkel, IJ; Heaney, ML; Jacobsen, E; McClain, K; Morris, SR; Murnane, A; Noble, R; Portnoy, A; Reedy, BA; Rodriguez-Galindo, C; Smith, DA; Vaiselbuh, S; Vassallo, R; Whitlock, J	1
Borchmann, P; Eichhorst, B; Hallek, M; Hellmann, M; Hübel, K; Kochanek, M; Kreuzer, K; Kreuzer, KA; Reiser, M	1
Kensler, TW; Roebuck, BD; Rogers, AE	1

Reviews

1 review(s) available for thiophenes and Hematologic Malignancies

Article	Year
[Hematology 2008]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fibrinolytic Agents; Hematologic Diseases; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism	2008

Article

Year

[Hematology 2008].

Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fibrinolytic Agents; Hematologic Diseases; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism

2008

Trials

2 trial(s) available for thiophenes and Hematologic Malignancies

Article	Year
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood, 2014, Oct-02, Volume: 124, Issue:14 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Patient Safety; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Time Factors; Young Adult	2014
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatric blood & cancer, 2017, Volume: 64, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Treatment Outcome; United States	2017

Article

Year

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.

Blood, 2014, Oct-02, Volume: 124, Issue:14

Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Patient Safety; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Time Factors; Young Adult

2014

A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.

Pediatric blood & cancer, 2017, Volume: 64, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Treatment Outcome; United States

2017

Other Studies

1 other study(ies) available for thiophenes and Hematologic Malignancies

Article	Year
Correspondence re: C.V. Rao, et al., Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res., 56: 3395-3398, 1996. Cancer research, 1997, Jul-01, Volume: 57, Issue:13 Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Hematologic Neoplasms; Imidazoles; Lymphoma; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes	1997